Last reviewed · How we verify
NCT00771381
A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer
Phase 2 trial testing 18F-FAZA PET scan in Breast Neoplasm in 23 participants. Terminated before completion.
4 February 2019
Quick facts
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 23 |
| Start date | 28 November 2008 |
| Primary completion | 4 February 2019 |
| Estimated completion | 4 February 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- 18F-FAZA PET scan — full drug profile →
- FluGlucoScan Injection (18F-FDB) PET scan — full drug profile →
Conditions studied
- Breast Neoplasm — all drugs for Breast Neoplasm →
Sponsor
AHS Cancer Control Alberta — full company profile →
Who can join
18 and older, female only, with Breast Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In about half the cases of breast cancer, there is hypoxic (no, or little oxygen) tissue present. Hypoxic cells can be resistant to treatment and may cause increased tumour growth. This study will use 18F-FAZA PET scans before surgery or treatment to assess whether patients have hypoxic tumours. The results will be compared to tissue samples removed during surgery and to the distribution of 18F-FDG.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00771381
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasm
Currently open trials in the same condition.
- NCT07054723 — Surviving Daily Life · recruiting
- NCT06839001 — CRYoablation for Small Tumors As Local Treatment - SIX Trial · Phase 3 · recruiting
- NCT06672302 — A Prospective Study to Develop and Clinically Validate an in Vitro Diagnostic Medical Device That Uses Blood to Classify · recruiting
- NCT06255808 — Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor · active not recruiting
- NCT06622967 — KNUCH CadAI-B-1(KCB-1) · NA · active not recruiting
Other AHS Cancer Control Alberta trials
Trials by the same sponsor.
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00771381 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
- Last refreshed: 22 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00771381.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing